Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence...

Full description

Bibliographic Details
Main Authors: Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-23271-0
id doaj-65ef3b7f9a184674b715885b4857dafc
record_format Article
spelling doaj-65ef3b7f9a184674b715885b4857dafc2021-05-23T11:13:05ZengNature Publishing GroupNature Communications2041-17232021-05-0112111110.1038/s41467-021-23271-0Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancerNindo B. Punturi0Sinem Seker1Vaishnavi Devarakonda2Aloran Mazumder3Rashi Kalra4Ching Hui Chen5Shunqiang Li6Tina Primeau7Matthew J. Ellis8Shyam M. Kavuri9Svasti Haricharan10Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery InstituteTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery InstituteLester and Sue Smith Breast Center, Baylor College of MedicineTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery InstituteLester and Sue Smith Breast Center, Baylor College of MedicineLester and Sue Smith Breast Center, Baylor College of MedicineDepartment of Medicine, Washington University in St. LouisDepartment of Medicine, Washington University in St. LouisLester and Sue Smith Breast Center, Baylor College of MedicineLester and Sue Smith Breast Center, Baylor College of MedicineTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery InstituteResistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence of endocrine treatment resistance.https://doi.org/10.1038/s41467-021-23271-0
collection DOAJ
language English
format Article
sources DOAJ
author Nindo B. Punturi
Sinem Seker
Vaishnavi Devarakonda
Aloran Mazumder
Rashi Kalra
Ching Hui Chen
Shunqiang Li
Tina Primeau
Matthew J. Ellis
Shyam M. Kavuri
Svasti Haricharan
spellingShingle Nindo B. Punturi
Sinem Seker
Vaishnavi Devarakonda
Aloran Mazumder
Rashi Kalra
Ching Hui Chen
Shunqiang Li
Tina Primeau
Matthew J. Ellis
Shyam M. Kavuri
Svasti Haricharan
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
Nature Communications
author_facet Nindo B. Punturi
Sinem Seker
Vaishnavi Devarakonda
Aloran Mazumder
Rashi Kalra
Ching Hui Chen
Shunqiang Li
Tina Primeau
Matthew J. Ellis
Shyam M. Kavuri
Svasti Haricharan
author_sort Nindo B. Punturi
title Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
title_short Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
title_full Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
title_fullStr Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
title_full_unstemmed Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
title_sort mismatch repair deficiency predicts response to her2 blockade in her2-negative breast cancer
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2021-05-01
description Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence of endocrine treatment resistance.
url https://doi.org/10.1038/s41467-021-23271-0
work_keys_str_mv AT nindobpunturi mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT sinemseker mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT vaishnavidevarakonda mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT aloranmazumder mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT rashikalra mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT chinghuichen mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT shunqiangli mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT tinaprimeau mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT matthewjellis mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT shyammkavuri mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
AT svastiharicharan mismatchrepairdeficiencypredictsresponsetoher2blockadeinher2negativebreastcancer
_version_ 1721430073718865920

Similar Items